Curcumin and neurodegenerative diseases

BioFactors

Volumn 39, Issue 1, 2013, Pages 122-132

  Monroy, Adriana ^a   Lithgow, Gordon J ^b   Alavez, Silvestre ^b  

^a SECRETARÍA DE SALUD   (Mexico)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Curcumin; Mammals; Model organisms; Neurodegenerative diseases

Indexed keywords

CURCUMIN;

AGING; ALZHEIMER DISEASE; CAENORHABDITIS ELEGANS; CELL CULTURE; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DRUG EFFECT; HUNTINGTON CHOREA; IN VITRO STUDY; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

AGING; ANIMALS; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; CURCUMIN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

ANIMALIA; CAENORHABDITIS ELEGANS; INVERTEBRATA; MAMMALIA; VERTEBRATA;

EID: 84874114347     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1063     Document Type: Review

References (141)

1. Prasad, S. and Aggarwal, B. B. In Benzie, I. F. F., Wachtel-Galor, S., Eds. ( 2011) Turmeric, the golden spice: from traditional medicine to modern medicine, CRC Press, Boca Raton.
2. Basnet, P. and Skalko-Basnet, N. ( 2011) Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 16, 4567-4598.
3. Darvesh, A. S., Aggarwal, B. B., and Bishayee, A. ( 2012) Curcumin and liver cancer: a review. Curr. Pharm. Biotechnol. 13, 218-228.
4. Jagtap, S., Meganathan, K., Wagh, V., Winkler, J., Hescheler, J., et al. ( 2009) Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr. Med. Chem. 16, 1451-1462.
5. Aggarwal, B. B. ( 2010) Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu. Rev. Nutr. 30, 173-199.
6. Alappat, L. and Awad, A. B. ( 2010) Curcumin and obesity: evidence and mechanisms. Nutr. Rev. 68, 729-738.
7. Sharma, R. A., Ireson, C. R., Verschoyle, R. D., Hill, K. A., Williams, M. L., et al. ( 2001) Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin. Cancer Res. 7, 1452-1458.
8. El-Agamy, D. S. ( 2010) Comparative effects of curcumin and resveratrol on aflatoxin B(1)-induced liver injury in rats. Arch. Toxicol. 84, 389-396.
9. Funk, J. L., Frye, J. B., Oyarzo, J. N., Kuscuoglu, N., Wilson, J., et al. ( 2006) Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum. 54, 3452-3464.
10. Funk, J. L., Oyarzo, J. N., Frye, J. B., Chen, G., Lantz, R. C., et al. ( 2006) Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. J. Nat. Prod. 69, 351-355.
11. Chandran, B. and Goel, A. ( 2012) A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother. Res. 26, 1719-1725.
12. Lee, K. S., Lee, B. S., Semnani, S., Avanesian, A., Um, C. Y., et al. ( 2010) Curcumin extends life span, improves health span, and modulates the expression of age-associated aging genes in Drosophila melanogaster. Rejuvenation Res. 13, 561-570.
13. Liao, V. H., Yu, C. W., Chu, Y. J., Li, W. H., Hsieh, Y. C., et al. ( 2011) Curcumin-mediated lifespan extension in Caenorhabditis elegans. Mech. Ageing Dev. 132, 480-487.
14. Pallauf, K. and Rimbach, G. ( 2012) Autophagy, polyphenols and healthy ageing. Ageing Res. Rev. 12, 237-252.
15. Kopito, R. R. and Ron, D. ( 2000) Conformational disease. Nat. Cell Biol. 2, E207-E209.
16. Kikis, E. A., Gidalevitz, T., and Morimoto, R. I. ( 2010) Protein homeostasis in models of aging and age-related conformational disease. Adv. Exp. Med. Biol. 694, 138-159.
17. Selkoe, D. J. ( 2003) Folding proteins in fatal ways. Nature 426, 900-904.
18. Haass, C. and Selkoe, D. J. ( 2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
19. Bates, G. ( 2003) Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361, 1642-1644.
20. Nussbaum, R. L. and Ellis, C. E. ( 2003) Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 348, 1356-1364.
21. Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., et al. ( 2011) Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 718-779.
22. Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., et al. ( 2011) Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 10, 377-393.
23. Schapira, A. H., Bezard, E., Brotchie, J., Calon, F., Collingridge, G. L., et al. ( 2006) Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov. 5, 845-854.
24. Ittner, L. M. and Gotz, J. ( 2011) Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12, 65-72.
25. Finefrock, A. E., Bush, A. I., and Doraiswamy, P. M. ( 2003) Current status of metals as therapeutic targets in Alzheimer's disease. J. Am. Geriatr. Soc. 51, 1143-1148.
26. Barnham, K. J. and Bush, A. I. ( 2008) Metals in Alzheimer's and Parkinson's diseases. Curr. Opin. Chem. Biol. 12, 222-228.
27. Ha, A. D. and Fung, V. S. ( 2012) Huntington's disease. Curr. Opin. Neurol. 25, 491-498.
28. Garcia-Alloza, M., Borrelli, L. A., Rozkalne, A., Hyman, B. T., and Bacskai, B. J. ( 2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem. 102, 1095-1104.
29. Ran, C., Xu, X., Raymond, S. B., Ferrara, B. J., Neal, K., et al. ( 2009) Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits. J. Am. Chem. Soc. 131, 15257-15261.
30. Lee, I., Yang, J., Lee, J. H., and Choe, Y. S. ( 2011) Synthesis and evaluation of 1-(4-[(1)(8)F]fluoroethyl)-7-(4′-methyl)curcumin with improved brain permeability for beta-amyloid plaque imaging. Bioorg. Med. Chem. Lett. 21, 5765-5769.
31. Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., et al. ( 2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901.
32. Hamaguchi, T., Ono, K., Murase, A., and Yamada, M. ( 2009) Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. Am. J. Pathol. 175, 2557-2565.
33. Wang, Y. J., Pan, M. H., Cheng, A. L., Lin, L. I., Ho, Y. S., et al. ( 1997) Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal. 15, 1867-1876.
34. Anand, P., Kunnumakkara, A. B., Newman, R. A., and Aggarwal, B. B. ( 2007) Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807-818.
35. Gota, V. S., Maru, G. B., Soni, T. G., Gandhi, T. R., Kochar, N., et al. ( 2010) Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J. Agric. Food Chem. 58, 2095-2099.
36. Kumar, A., Ahuja, A., Ali, J., and Baboota, S. ( 2010) Conundrum and therapeutic potential of curcumin in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 27, 279-312.
37. Yallapu, M. M., Jaggi, M., and Chauhan, S. C. ( 2012) Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. Today 17, 71-80.
38. Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., et al. ( 2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21, 2895-2900.
39. Sarkar, F. H., Li, Y., Wang, Z., and Padhye, S. ( 2010) Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr. Pharm. Des. 16, 1801-1812.
40. Shehzad, A., Wahid, F., and Lee, Y. S. ( 2010) Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm. 343, 489-499.
41. Singh, R. and Sharma, P. ( 2011) Hepatoprotective effect of curcumin on lindane-induced oxidative stress in male wistar rats. Toxicol. Int. 18, 124-129.
42. Girish, C. and Pradhan, S. C. ( 2012) Hepatoprotective activities of picroliv, curcumin, and ellagic acid compared to silymarin on carbon-tetrachloride-induced liver toxicity in mice. J. Pharmacol. Pharmacother. 3, 149-155.
43. Morsy, M. A., Abdalla, A. M., Mahmoud, A. M., Abdelwahab, S. A., and Mahmoud, M. E. ( 2012) Protective effects of curcumin, alpha-lipoic acid, and N-acetylcysteine against carbon tetrachloride-induced liver fibrosis in rats. J. Physiol. Biochem. 68, 29-35.
44. Singh, M., Sasi, P., Gupta, V. H., Rai, G., Amarapurkar, D. N., et al. ( 2012) Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model. Hum. Exp. Toxicol. 31, 788-797.
45. Srivastava, R., Dikshit, M., Srimal, R. C., and Dhawan, B. N. ( 1985) Anti-thrombotic effect of curcumin. Thromb. Res. 40, 413-417.
46. Prakash, P., Misra, A., Surin, W. R., Jain, M., Bhatta, R. S., et al. ( 2011) Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemia-reperfusion and thrombosis. Thromb. Res. 127, 111-118.
47. Miriyala, S., Panchatcharam, M., and Rengarajulu, P. ( 2007) Cardioprotective effects of curcumin. Adv. Exp. Med. Biol. 595, 359-377.
48. Duan, W., Yang, Y., Yan, J., Yu, S., Liu, J., et al. ( 2012) The effects of curcumin post-treatment against myocardial ischemia and reperfusion by activation of the JAK2/STAT3 signaling pathway. Basic Res. Cardiol. 107, 263.
49. Izem-Meziane, M., Djerdjouri, B., Rimbaud, S., Caffin, F., Fortin, D., et al. ( 2012) Catecholamine-induced cardiac mitochondrial dysfunction and mPTP opening: protective effect of curcumin. Am. J. Physiol. Heart Circ. Physiol. 302, H665-H674.
50. Reddy, R. C., Vatsala, P. G., Keshamouni, V. G., Padmanaban, G., and Rangarajan, P. N. ( 2005) Curcumin for malaria therapy. Biochem. Biophys. Res. Commun. 326, 472-474.
51. Perez-Arriaga, L., Mendoza-Magana, M. L., Cortes-Zarate, R., Corona-Rivera, A., Bobadilla-Morales, L., et al. ( 2006) Cytotoxic effect of curcumin on Giardia lamblia trophozoites. Acta Trop. 98, 152-161.
52. De, R., Kundu, P., Swarnakar, S., Ramamurthy, T., Chowdhury, A., et al. ( 2009) Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob. Agents Chemother. 53, 1592-1597.
53. Na, H. S., Cha, M. H., Oh, D. R., Cho, C. W., Rhee, J. H., et al. ( 2011) Protective mechanism of curcumin against Vibrio vulnificus infection. FEMS Immunol. Med. Microbiol. 63, 355-362.
54. Nagajyothi, F., Zhao, D., Weiss, L. M., and Tanowitz, H. B. ( 2012) Curcumin treatment provides protection against Trypanosoma cruzi infection. Parasitol. Res. 110, 2491-2499.
55. Ye, J. and Zhang, Y. ( 2012) Curcumin protects against intracellular amyloid toxicity in rat primary neurons. Int. J. Clin. Exp. Med. 5, 44-49.
56. Lavoie, S., Chen, Y., Dalton, T. P., Gysin, R., Cuénod, M., et al. ( 2009) Curcumin, quercetin, and tBHQ modulate glutathione levels in astrocytes and neurons: importance of the glutamate cysteine ligase modifier subunit. J. Neurochem. 108, 1410-1422.
57. Karlstetter, M., Lippe, E., Walczak, Y., Moehle, C., Aslanidis, A., et al. ( 2011) Curcumin is a potent modulator of microglial gene expression and migration. J. Neuroinflamm. 8, 125.
58. Wang, J., Zhang, Y. J., and Du, S. ( 2012) The protective effect of curcumin on Abeta induced aberrant cell cycle reentry on primary cultured rat cortical neurons. Eur. Rev. Med. Pharmacol. Sci. 16, 445-454.
59. Ortiz-Ortiz, M. A., Morán, J. M., Ruiz-Mesa, L. M., Niso-Santano, M., Bravo-SanPedro, J. M., et al. ( 2010) Curcumin exposure induces expression of the Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells. Neurosci. Lett. 468, 120-124.
60. Jiang, H., Tian, X., Guo, Y., Duan, W., Bu, H., et al. ( 2011) Activation of nuclear factor erythroid 2-related factor 2 cytoprotective signaling by curcumin protect primary spinal cord astrocytes against oxidative toxicity. Biol. Pharm. Bull. 34, 1194-1197.
61. Darvesh, A. S., Carroll, R. T., Bishayee, A., Novotny, N. A., Geldenhuys, W. J., et al. ( 2012) Curcumin and neurodegenerative diseases: a perspective. Expert Opin. Investig. Drugs 21, 1123-1140.
62. Aggarwal, B. B. and Sung, B. ( 2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci. 30, 85-94.
63. Kelsey, N. A., Wilkins, H. M., and Linseman, D. A. ( 2010) Nutraceutical antioxidants as novel neuroprotective agents. Molecules 15, 7792-7814.
64. Agrawal, R., Mishra, B., Tyagi, E., Nath, C., and Shukla, R. ( 2010) Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol. Res. 61, 247-252.
65. Zhou, H., Beevers, C. S., and Huang, S. ( 2011) The targets of curcumin. Curr. Drug Targets 12, 332-347.
66. Ono, K., Hasegawa, K., Naiki, H., and Yamada, M. ( 2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 75, 742-750.
67. Kim, H., Park, B. S., Lee, K. G., Choi, C. Y., Jang, S. S., et al. ( 2005) Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J. Agric. Food Chem. 53, 8537-8541.
68. Shytle, R. D., Bickford, P. C., Rezai-zadeh, K., Hou, L., Zeng, J., et al. ( 2009) Optimized turmeric extracts have potent anti-amyloidogenic effects. Curr. Alzheimer Res. 6, 564-571.
69. Guo, J. P., Yu, S., and McGeer, P. L. ( 2010) Simple in vitro assays to identify amyloid-beta aggregation blockers for Alzheimer's disease therapy. J. Alzheimers Dis. 19, 1359-1370.
70. Varghese, K., Molnar, P., Das, M., Bhargava, N., Lambert, S., et al. ( 2010) A new target for amyloid beta toxicity validated by standard and high-throughput electrophysiology. PLoS One 5, e8643.
71. Zhang, C., Browne, A., Child, D., and Tanzi, R. E. ( 2010) Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J. Biol. Chem. 285, 28472-28480.
72. Kuner, P., Schubenel, R., and Hertel, C. ( 1998) Beta-amyloid binds to p57NTR and activates NFkappaB in human neuroblastoma cells. J. Neurosci. Res. 54, 798-804.
73. Kim, D. S., Park, S. Y., and Kim, J. K. ( 2001) Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci. Lett. 303, 57-61.
74. Ono, K. and Yamada, M. ( 2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J. Neurochem. 97, 105-115.
75. Cho, J. W., Lee, K. S., and Kim, C. W. ( 2007) Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int. J. Mol. Med. 19, 469-474.
76. Cole, G. M., Teter, B., and Frautschy, S. A. ( 2007) Neuroprotective effects of curcumin. Adv. Exp. Med. Biol. 595, 197-212.
77. Rogers, J. T., Randall, J. D., Eder, P. S., Huang, X., Bush, A. I., et al. ( 2002) Alzheimer's disease drug discovery targeted to the APP mRNA 5′untranslated region. J. Mol. Neurosci. 19, 77-82.
78. Jomova, K., Vondrakova, D., Lawson, M., and Valko, M. ( 2010) Metals, oxidative stress and neurodegenerative disorders. Mol. Cell. Biochem. 345, 91-104.
79. Baum, L. and Ng, A. ( 2004) Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis. 6, 367-377; discussion 443-369.
80. Barik, A., Mishra, B., Kunwar, A., Kadam, R. M., Shen, L., et al. ( 2007) Comparative study of copper(II)-curcumin complexes as superoxide dismutase mimics and free radical scavengers. Eur. J. Med. Chem. 42, 431-439.
81. Beal, M. F. ( 2001) Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2, 325-334.
82. Wang, J., Du, X. X., Jiang, H., and Xie, J. X. ( 2009) Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 cells. Biochem. Pharmacol. 78, 178-183.
83. Jaisin, Y., Thampithak, A., Meesarapee, B., Ratanachamnong, P., Suksamrarn, A., et al. ( 2011) Curcumin I protects the dopaminergic cell line SH-SY5Y from 6-hydroxydopamine-induced neurotoxicity through attenuation of p53-mediated apoptosis. Neurosci. Lett. 489, 192-196.
84. Chen, J., Tang, X. Q., Zhi, J. L., Cui, Y., Yu, H. M., et al. ( 2006) Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis 11, 943-953.
85. Yu, S., Zheng, W., Xin, N., Chi, Z. H., Wang, N. Q., et al. ( 2010) Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Res. 13, 55-64.
86. Novak, J. and Vanek, Z. ( 1992) Screening for a new generation of anthelminthic compounds. In vitro selection of the nematode Caenorhabditis elegans for ivermectin resistance. Folia Microbiol. 37, 237-238.
87. Davies, A. G. and McIntire, S. L. ( 2004) Using C. elegans to screen for targets of ethanol and behavior-altering drugs. Biol. Proced Online 6, 113-119.
88. Kwok, T. C., Ricker, N., Fraser, R., Chan, A. W., Burns, A., et al. ( 2006) A small-molecule screen in C. elegans yields a new calcium channel antagonist. Nature 441, 91-95.
89. Tampakakis, E., Okoli, I., and Mylonakis, E. ( 2008) A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nat. Protoc. 3, 1925-1931.
90. Moy, T. I., Conery, A. L., Larkins-Ford, J., Wu, G., Mazitschek, R., et al. ( 2009) High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem. Biol. 4, 527-533.
91. Lemieux, G. A., Liu, J., Mayer, N., Bainton, R. J., Ashrafi, K., et al. ( 2011) A whole-organism screes identifies new regulators of fat storage. Nat. Chem. Biol. 7, 206-213.
92. Harrington, L. A. and Harley, C. B. ( 1988) Effect of vitamin E on lifespan and reproduction in Caenorhabditis elegans. Mech. Ageing Dev. 43, 71-78.
93. Adachi, H. and Ishii, N. ( 2000) Effects of tocotrienols on life span and protein carbonylation in Caenorhabditis elegans. J. Gerontol. A Biol. Sci. Med. Sci. 55, B280-B285.
94. Melov, S., Ravenscroft, J., Malik, S., Gill, M. S., Walker, D. W., et al. ( 2000) Extension of life-span with superoxide dismutase/catalase mimetics. Science 289, 1567-1569.
95. Fei, Y. J., Inoue, K., and Ganapathy, V. ( 2003) Structural and functional characteristics of two sodium-coupled dicarboxylate transporters (ceNaDC1 and ceNaDC2) from Caenorhabditis elegans and their relevance to life span. J. Biol. Chem. 278, 6136-6144.
96. Evason, K., Huang, C., Yamben, I., Covey, D. F., and Kornfeld, K. ( 2005) Anticonvulsant medications extend worm life-span. Science 307, 258-262.
97. Benedetti, M. G., Foster, A. L., Vantipalli, M. C., White, M. P., Sampayo, J. N., et al. ( 2008) Compounds that confer thermal stress resistance and extended lifespan. Exp. Gerontol. 43, 882-891.
98. McColl, G., Killilea, D. W., Hubbard, A. E., Vantipalli, M. C., Melov, S., et al. ( 2008) Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans. J. Biol. Chem. 283, 350-357.
99. Srivastava, D., Arya, U., SoundaraRajan, T., Dwivedi, H., Kumar, S., et al. ( 2008) Reserpine can confer stress tolerance and lifespan extension in the nematode C. elegans. Biogerontology 9, 309-316.
100. Pietsch, K., Saul, N., Menzel, R., Sturzenbaum, S. R., and Steinberg, C. E. ( 2009) Quercetin mediated lifespan extension in Caenorhabditis elegans is modulated by age-1, daf-2, sek-1 and unc-43. Biogerontology 10, 565-578.
101. Saul, N., Pietsch, K., Menzel, R., Sturzenbaum, S. R., and Steinberg, C. E. ( 2009) Catechin induced longevity in C. elegans: from key regulator genes to disposable soma. Mech. Ageing Dev. 130, 477-486.
102. Honda, Y., Tanaka, M., and Honda, S. ( 2010) Trehalose extends longevity in the nematode Caenorhabditis elegans. Aging Cell 9, 558-569.
103. Onken, B. and Driscoll, M. ( 2010) Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One 5, e8758.
104. Alavez, S., Vantipalli, M. C., Zucker, D. J., Klang, I. M., and Lithgow, G. J. ( 2011) Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature 472, 226-229.
105. Powolny, A. A., Singh, S. V., Melov, S., Hubbard, A., and Fisher, A. L. ( 2011) The garlic constituent diallyl trisulfide increases the lifespan of C. elegans via skn-1 activation. Exp. Gerontol. 46, 441-452.
106. Wu, Z., Smith, J. V., Paramasivam, V., Butko, P., Khan, I., et al. ( 2002) Ginkgo biloba extract EGb 761 increases stress resistance and extends life span of Caenorhabditis elegans. Cell. Mol. Biol. 48, 725-731.
107. Wilson, M. A., Shukitt-Hale, B., Kalt, W., Ingram, D. K., Joseph, J. A., et al. ( 2006) Blueberry polyphenols increase lifespan and thermotolerance in Caenorhabditis elegans. Aging Cell 5, 59-68.
108. Bass, T. M., Weinkove, D., Houthoofd, K., Gems, D., and Partridge, L. ( 2007) Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech. Ageing Dev. 128, 546-552.
109. Strong, R., Miller, R. A., Astle, C. M., Baur, J. A., de Cabo, R., et al. ( 2012) Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J. Gerontol. A Biol. Sci. Med. Sci.
110. Link, C. D., Taft, A., Kapulkin, V., Duke, K., Kim, S., et al. ( 2003) Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol. Aging 24, 397-413.
111. Kraemer, B. C., Zhang, B., Leverenz, J. B., Thomas, J. H., Trojanowski, J. Q., et al. ( 2003) Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc. Natl. Acad. Sci. USA 100, 9980-9985.
112. Miyasaka, T., Ding, Z., Gengyo-Ando, K., Oue, M., Yamaguchi, H., et al. ( 2005) Progressive neurodegeneration in C. elegans model of tauopathy. Neurobiol. Dis. 20, 372-383.
113. Lakso, M., Vartiainen, S., Moilanen, A. M., Sirvio, J., Thomas, J. H., et al. ( 2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 86, 165-172.
114. Cao, S., Gelwix, C. C., Caldwell, K. A., and Caldwell, G. A. ( 2005) Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J. Neurosci. 25, 3801-3812.
115. Hamamichi, S., Rivas, R. N., Knight, A. L., Cao, S., Caldwell, K. A., et al. ( 2008) Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc. Natl. Acad. Sci. USA 105, 728-733.
116. van Ham, T. J., Thijssen, K. L., Breitling, R., Hofstra, R. M., Plasterk, R. H., et al. ( 2008) C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet. 4, e1000027.
117. Park, K. W. and Li, L. ( 2008) Cytoplasmic expression of mouse prion protein causes severe toxicity in Caenorhabditis elegans. Biochem. Biophys. Res. Commun. 372, 697-702.
118. Gidalevitz, T., Ben-Zvi, A., Ho, K. H., Brignull, H. R., and Morimoto, R. I. ( 2006) Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311, 1471-1474.
119. Gidalevitz, T., Krupinski, T., Garcia, S., and Morimoto, R. I. ( 2009) Destabilizing protein polymorphisms in the genetic background direct phenotypic expression of mutant SOD1 toxicity. PLoS Genet. 5, e1000399.
120. Alavez, S. and Lithgow, G. J. ( 2012) Pharmacological maintenance of protein homeostasis could postpone age-related disease. Aging Cell 11, 187-191.
121. Hsu, A. L., Murphy, C. T., and Kenyon, C. ( 2003) Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 300, 1142-1145.
122. Rincon-Limas, D. E., Jensen, K., and Fernandez-Funez, P. ( 2012) Drosophila models of proteinopathies: the little fly that could. Curr. Pharm. Des. 18, 1108-1122.
123. Caesar, I., Jonson, M., Nilsson, K. P., Thor, S., and Hammarstrom, P. ( 2012) Curcumin promotes A-beta fibrillation and reduces neurotoxicity in transgenic Drosophila. PLoS One 7, e31424.
124. Strong, R., Miller, R. A., Astle, C. M., Floyd, R. A., Flurkey, K., et al. ( 2008) Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell 7, 641-650.
125. Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., et al. ( 2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395.
126. Miller, R. A., Harrison, D. E., Astle, C. M., Baur, J. A., Boyd, A. R., et al. ( 2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. A Biol. Sci. Med. Sci. 66, 191-201.
127. Frautschy, S. A., Hu, W., Kim, P., Miller, S. A., Chu, T., et al. ( 2001) Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol. Aging 22, 993-1005.
128. Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., et al. ( 2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 8370-8377.
129. Begum, A. N., Jones, M. R., Lim, G. P., Morihara, T., Kim, P., et al. ( 2008) Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J. Pharmacol. Exp. Ther. 326, 196-208.
130. Pan, R., Qiu, S., Lu, D. X., and Dong, J. ( 2008) Curcumin improves learning and memory ability and its neuroprotective mechanism in mice. Chin. Med. J. 121, 832-839.
131. Pandey, N., Strider, J., Nolan, W. C., Yan, S. X., and Galvin, J. E. ( 2008) Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol. 115, 479-489.
132. Zbarsky, V., Datla, K. P., Parkar, S., Rai, D. K., Aruoma, O. I., et al. ( 2005) Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic. Res. 39, 1119-1125.
133. Tripanichkul, W. and Jaroensuppaperch, E. O. ( 2012) Curcumin protects nigrostriatal dopaminergic neurons and reduces glial activation in 6-hydroxydopamine hemiparkinsonian mice model. Int. J. Neurosci. 122, 263-270.
134. Vajragupta, O., Boonchoong, P., Watanabe, H., Tohda, M., Kummasud, N., et al. ( 2003) Manganese complexes of curcumin and its derivatives: evaluation for the radical scavenging ability and neuroprotective activity. Free Radic. Biol. Med. 35, 1632-1644.
135. Rajeswari, A. ( 2006) Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Eur. Rev. Med. Pharmacol. Sci. 10, 157-161.
136. Rajeswari, A. and Sabesan, M. ( 2008) Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacology 16, 96-99.
137. Mythri, R. B., Harish, G., Dubey, S. K., Misra, K., and Bharath, M. M. ( 2011) Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitrite-mediated nitrosative stress and damage of brain mitochondria in vitro: implications for Parkinson's disease. Mol. Cell. Biochem. 347, 135-143.
138. Hickey, M. A., Zhu, C., Medvedeva, V., Lerner, R. P., Patassini, S., et al. ( 2012) Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Mol. Neurodegener. 7, 12.
139. Ng, T. P., Chiam, P. C., Lee, T., Chua, H. C., Lim, L., et al. ( 2006) Curry consumption and cognitive function in the elderly. Am. J. Epidemiol. 164, 898-906.
140. Baum, L., Lam, C. W., Cheung, S. K., Kwok, T., Lui, V., et al. ( 2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 28, 110-113.
141. Ringman, J. M., Younkin, S. G., Pratico, D., Seltzer, W., Cole, G. M., et al. ( 2008) Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71, 85-92.